OBJECTIVES: To establish the relationship between the functional impairment experienced by Chronic fatigue syndrome (CFS) patients and the symptoms frequently experienced by those with CFS; specifically cognitive impairment, fatigue and orthostatic symptoms. DESIGN: Cross sectional questionnaire survey. SETTING: Specialist CFS Clinical Service. SUBJECTS: Ninety-nine Fukuda diagnosed CFS and 64-matched controls. MAIN OUTCOME MEASURES: Symptom and functional assessment tools completed and returned by post included; PROMIS HAQ (Patient-Reported Outcomes Measurement Information System, Health Assessment Questionnaire), CFQ (Cognitive Failures Questionnaire), FIS (Fatigue Impact Scale) and OGS (Orthostatic Grading Scale) assessment tools. RESULTS: CFS patients experience greater functional impairment than controls [mean (95% CI) PROMIS HAQ scores CFS 36 (31-42) vs. controls 6 (2-10); P < 0.0001], especially in the functional domains of activities and reach. Poorer functional ability impairment is significantly associated with greater cognitive impairment (P = 0.0002, r = 0.4), fatigue (P < 0.0001, r = 0.5) and orthostatic symptoms (P < 0.0001, r = 0.6). However, only orthostatic symptoms (OGS) independently associated with functional impairment (beta = 0.4, P = 0.01). CONCLUSION: Treatment of orthostatic symptoms in CFS has the potential to improve functional capacity and so improve quality of life.
OBJECTIVES: To establish the relationship between the functional impairment experienced by Chronic fatigue syndrome (CFS) patients and the symptoms frequently experienced by those with CFS; specifically cognitive impairment, fatigue and orthostatic symptoms. DESIGN: Cross sectional questionnaire survey. SETTING: Specialist CFS Clinical Service. SUBJECTS: Ninety-nine Fukuda diagnosed CFS and 64-matched controls. MAIN OUTCOME MEASURES: Symptom and functional assessment tools completed and returned by post included; PROMIS HAQ (Patient-Reported Outcomes Measurement Information System, Health Assessment Questionnaire), CFQ (Cognitive Failures Questionnaire), FIS (Fatigue Impact Scale) and OGS (Orthostatic Grading Scale) assessment tools. RESULTS: CFS patients experience greater functional impairment than controls [mean (95% CI) PROMIS HAQ scores CFS 36 (31-42) vs. controls 6 (2-10); P < 0.0001], especially in the functional domains of activities and reach. Poorer functional ability impairment is significantly associated with greater cognitive impairment (P = 0.0002, r = 0.4), fatigue (P < 0.0001, r = 0.5) and orthostatic symptoms (P < 0.0001, r = 0.6). However, only orthostatic symptoms (OGS) independently associated with functional impairment (beta = 0.4, P = 0.01). CONCLUSION: Treatment of orthostatic symptoms in CFS has the potential to improve functional capacity and so improve quality of life.
Authors: B M Carruthers; M I van de Sande; K L De Meirleir; N G Klimas; G Broderick; T Mitchell; D Staines; A C P Powles; N Speight; R Vallings; L Bateman; B Baumgarten-Austrheim; D S Bell; N Carlo-Stella; J Chia; A Darragh; D Jo; D Lewis; A R Light; S Marshall-Gradisnik; I Mena; J A Mikovits; K Miwa; M Murovska; M L Pall; S Stevens Journal: J Intern Med Date: 2011-08-22 Impact factor: 8.989
Authors: Even Fagermoen; Dag Sulheim; Anette Winger; Anders M Andersen; Nils Tore Vethe; J Philip Saul; Erik Thaulow; Vegard Bruun Wyller Journal: BMC Res Notes Date: 2012-08-07
Authors: Julia L Newton; Andreas Finkelmeyer; George Petrides; James Frith; Tim Hodgson; Laura Maclachlan; Guy MacGowan; Andrew M Blamire Journal: Open Heart Date: 2016-06-24
Authors: Julia L Newton; James Frith; Danielle Powell; Kate Hackett; Katharine Wilton; Simon Bowman; Elizabeth Price; Colin Pease; Jacqueline Andrews; Paul Emery; John Hunter; Monica Gupta; Saravanan Vadivelu; Ian Giles; David Isenberg; Peter Lanyon; Adrian Jones; Marian Regan; Annie Cooper; Robert Moots; Nurhan Sutcliffe; Michele Bombardieri; Costantino Pitzalis; John McLaren; Steven Young-Min; Bhaskar Dasgupta; Bridget Griffiths; Dennis Lendrem; Sheryl Mitchell; Wan-Fai Ng Journal: Ann Rheum Dis Date: 2012-05-05 Impact factor: 19.103